BOTHELL, Wash., April 06, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , a clinical-stage biopharmaceutical company, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. In connection with this offering, Alder expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of common stock.
J.P. Morgan Securities LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was effective on filing on June 2, 2015. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525 ext. 6142, or by email at [email protected]; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by phone at 1-800-326-5897, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
| Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 [email protected] [email protected] | Investor Relations Contacts: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected] |


SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 



